Manages hypertension. ANDA 203018, held by Sciegen Pharms. Hydrochlorothiazide.
As of Nov 16, 2026, ANDA 203018 (Hydrochlorothiazide), held by Sciegen Pharms, was first approved by FDA on Jul 23, 2014, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE: Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 23, 2014 | Original application | Approved | None posted |
| Hydrochlorothiazide25MG · tablet;oral | Hydrochlorothiazide | Rx |
| Hydrochlorothiazide50MG · tablet;oral | Hydrochlorothiazide | Rx |
| Aug 20, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 23, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters